Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends

Pharma Giants' SG&A Expenses: A Decade of Divergence

__timestampAlnylam Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 20144452600034916000
Thursday, January 1, 20156061000036949000
Friday, January 1, 20168935400045240000
Sunday, January 1, 201719936500062416000
Monday, January 1, 201838235900081289000
Tuesday, January 1, 2019479005000100359000
Wednesday, January 1, 2020588420000105326000
Friday, January 1, 2021620639000122356000
Saturday, January 1, 2022770658000152848000
Sunday, January 1, 2023795646000184259000
Monday, January 1, 2024975526000
Loading chart...

Infusing magic into the data realm

SG&A Expense Trends: Alnylam Pharmaceuticals vs. Corcept Therapeutics

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Alnylam Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.

A Decade of Growth and Strategy

From 2014 to 2023, Alnylam Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by approximately 1,700%. This reflects their aggressive expansion and investment in market presence. In contrast, Corcept Therapeutics has experienced a more moderate increase of around 430%, indicating a more conservative approach.

Strategic Implications

These trends highlight differing strategic priorities: Alnylam's focus on rapid growth and market penetration versus Corcept's steady, controlled expansion. Investors and industry analysts should consider these financial strategies when evaluating the long-term potential and risk profiles of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025